Insmed To Present at the 41st Annual J.P. Morgan Healthcare Conference

Insmed Incorporated (Nasdaq:INSM) will present at the 41st Annual J.P.

Rhea-AI Summary

Insmed Incorporated (Nasdaq:INSM) will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on January 9, 2023, at 4:30 p.m. PT (7:30 p.m. ET). The session will include a presentation and a Q&A segment, which will be streamed live via the investor relations section of Insmed's website. The webcast will remain available for 30 days post-event. Insmed focuses on transforming the lives of patients with serious and rare diseases, with its first therapy approved for a chronic lung disease and a promising pipeline for unmet medical needs.

Argus Session date unavailable

-4.00% session move Open Argus

Details

News Market Reaction – INSM

The recorded move for INSM in the trading session of this news was -4.00%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRIDGEWATER, N.J., Jan. 3, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the 41^st Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9, 2023 at 4:30 p.m. PT (7:30 p.m. ET).

The presentation and question and answer session will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. The webcast will be archived for a period of 30 days following the conclusion of the live event.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.

Contact:

Investors:

Eleanor Barisser
Associate Director, Investor Relations 
Insmed
(718) 594-5332
eleanor.barisser@insmed.com 

Media:

Mandy Fahey 
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-the-41st-annual-jp-morgan-healthcare-conference-301711655.html

SOURCE Insmed Incorporated

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Insmed presenting at the J.P. Morgan Healthcare Conference 2023?

Insmed is set to present at the 41^st Annual J.P. Morgan Healthcare Conference on January 9, 2023, discussing its mission and pipeline.

When will Insmed's presentation at the J.P. Morgan Conference take place?

The presentation will take place on January 9, 2023, at 4:30 p.m. PT (7:30 p.m. ET).

How can I watch Insmed's presentation at the J.P. Morgan Conference?

The presentation will be webcast live and can be accessed on Insmed's investor relations website.

Is there an archive of Insmed's presentation at the J.P. Morgan Conference?

Yes, the webcast will be archived for 30 days after the live event.

What is the primary focus of Insmed as a biopharmaceutical company?

Insmed aims to transform the lives of patients with serious and rare diseases, with a focus on unmet medical needs.